IDO1 and cancer: Although a small molecule IDO1 inhibitor did not show promising results in a cancer immunotherapy phase III clinical trial [35], IDO inhibitors could impede skeletal muscle atrophy, which is caused by overexpression of IDO in tumors and mediated by Trp metabolism.